Introduction
Erythema migrans (EM) is the most frequent manifestation of Lyme borreliosis. 1 The skin lesion is usually solitary, but may be multiple. Multiple EM is defined as the presence of 2 EM skin lesions 1, 2 and is interpreted as the consequence of haematogenous dissemination of borreliae. 3 Although antibiotic therapy is highly effective in resolving EM, a considerable proportion of patients complain of post-Lyme symptoms. 4 IDSA guidelines recommend the same management for both solitary EM and multiple EM; 5 however, only one study, in the USA, has specifically addressed the treatment of multiple EM. 6 The primary objective of this trial was to assess the noninferiority of 14 day oral doxycycline in comparison with 14 day intravenous ceftriaxone for the treatment of adult European patients with disseminated Lyme borreliosis manifested as multiple EM. The primary efficacy outcome was incomplete response at the 12 month visit. Secondary efficacy outcomes were incomplete response at 14 days, at 2 and 6 months, and at the final evaluable visit. A secondary objective of the study was to compare the presence of non-specific symptoms in patients and controls.
Patients and methods
The study was approved by the Medical Ethics Committee of the Ministry of Health of the Republic of Slovenia (No. 83/05/10) and was registered at http://clinicaltrials.gov (identifier NCT01163994). if they had multiple EM defined according to European criteria. 2 In short, EM is defined as an expanding red or bluish-red patch, with or without central clearing, that develops days to weeks after the bite of a tick or exposure to ticks in a Lyme borreliosis endemic region. For a reliable diagnosis, the lesion must reach 5 cm in diameter. If the lesion is ,5 cm in diameter, a history of tick bite, a delay in appearance (after the tick bite) of at least 2 days and an expanding rash at the site of the tick bite are required. 2 Multiple EM is defined as the presence of two or more skin lesions, one of which must fulfil the size criteria for solitary EM. 1 Patients were excluded if they: were pregnant or lactating; had received an antibiotic with known anti-borrelial activity within the previous 10 days; had an extracutaneous manifestation of Lyme borreliosis; had received ,10 days of the study antibiotic; or had an intercurrent episode of Lyme borreliosis during follow-up. Patients with multiple EM were allocated to 14 day treatment with either 100 mg of oral doxycycline twice daily or 2 g of intravenous ceftriaxone once daily based on arrival order at the clinic so that every patient received one of the two alternative treatment options. Drug safety was monitored by recording adverse events and by laboratory testing.
Setting and participants
Each patient was asked to refer a family member or a friend of the same age +5 years without any history of Lyme borreliosis to serve as a control.
All patients and controls gave informed consent prior to participation in the study.
Evaluation of patients and control subjects
This was an open clinical trial. At baseline and follow-up at 14 days and 2, 6 and 12 months, patients were examined physically and were asked an open question about health-related symptoms. Symptoms that had newly developed or worsened since the onset of the EM and which had no other known medical explanation were regarded as constitutional symptoms at enrolment or as post-Lyme symptoms at follow-up visits.
Afterwards, patients completed a written questionnaire asking whether they had had any of eight non-specific symptoms (fatigue, arthralgias, headache, myalgias, paraesthesias, memory difficulties, concentration difficulties and irritability) within the preceding week.
At enrolment, lumbar puncture was proposed for patients. It was performed in those who consented with the procedure.
On day 14, patients were asked about medication compliance and adverse events.
Complete response to treatment was defined as a return to pre-Lyme health status. Partial response was defined as the presence of post-Lyme symptoms, while occurrence of new objective signs of Lyme borreliosis and/ or persistence of borreliae as detected by culture of skin re-biopsy sample and/or persistence of EM at 2 months post-treatment were interpreted as failure. Persistence of EM was defined as EM that could still be seen in daylight and at room temperature. Since treatment failure is a rare event, 4 we grouped failures and partial responses together as incomplete response.
Control subjects completed the same eight-symptom questionnaire as the patients within 14 days of the examination date of the corresponding patient at enrolment and again at 6 and 12 months.
Patients and controls graded the severity of each individual symptom on a 10 cm visual analogue scale (10 " most severe). 4 
Laboratory evaluation and microbiological analysis
Data on complete blood cell counts and basic serum chemistry were collected at baseline and 14 days later. CSF samples collected at enrolment were analysed for cell counts and protein and glucose levels. A leucocyte count .5%10 6 cells/L (pleocytosis) was considered abnormal. Immunoglobulin classes M and G (IgM and IgG) and albumin levels were determined in serum and CSF samples. Serum and CSF IgM antibodies to OspC and VlsE, and IgG antibodies to VlsE borrelial antigens were determined with indirect chemiluminescence immunoassay (LIAISON, Diasorin, Italy) and results interpreted according to the manufacturer's instructions.
Intrathecal synthesis of borrelial antibodies was determined as described by Reiber and Peter; 7 antibody index values .1.4 indicating intrathecal production of borrelial antibodies.
At baseline, a 3 mm punch biopsy skin specimen was obtained from the expanding edge of the primary EM and placed in 6 mL of modified KellyPettenkofer (MKP) culture medium. If the first skin specimen was culture positive for borreliae, a second biopsy was collected from the same site 2-3 months after the first. Cultures were examined weekly by dark-field microscopy for the presence of spirochetes and were interpreted as negative if no growth was established by 9 weeks. Baseline blood samples were cultured for borreliae as previously described. 8 Isolates were identified to species level using large restriction fragment pattern analysis after MluI restriction 8 or realtime PCR targeting the HBB gene. 9 
Statistical analyses
Sample size for assessment of the efficacy of treatment regimens was based on the assumption that 5% of patients receiving doxycycline would have incomplete response at 12 months post-treatment 5 and that the primary efficacy outcome would occur with the same frequency in both treatment groups. To obtain a 90% statistical power with a one-sided a " 0.05, 83 patients per group were necessary to establish the non-inferiority of doxycycline compared with ceftriaxone treatment, with an absolute margin of non-inferiority 10 percentage points. To account for attrition, the required sample size was estimated to be about 100 patients per group.
Categorical data were summarized as frequencies (%) and numerical data as medians (IQR).
The proportion of patients with incomplete response at 12 months post-enrolment and the associated one-sided 95% CI for the difference (doxycycline versus ceftriaxone) were estimated using the normal approximation with continuity correction. The same analysis was used to estimate the proportion of incomplete responders at the other timepoints and at the final evaluable visit. Non-inferiority of doxycycline was accepted if the upper bound limit of the one-sided 95% CI around the estimate of the absolute difference was 10 percentage points.
The median duration of the EM was calculated using the Kaplan-Meier method; the log-rank test was used to test the difference between the duration curves of the two treatment groups.
The association between incomplete response and other covariates (sex, age and presence of constitutional symptoms at enrolment) was estimated using mixed-effects logistic regression, adjusting the analysis for treatment and time from enrolment (used as a categorical variable). To account for multiple measurements in each patient, random intercept by patient ID was included in the model. 10 Results were presented as ORs with 95% CIs. R statistical language was used for the analyses. 11 
Results

Comparison of patients' pretreatment characteristics
Out of 234 multiple EM patients evaluated for participation in the trial, 19 met exclusion criteria (prior antibiotic therapy 12, pregnant or lactating 3, declined to participate 1, received ,10 days of study antibiotic 2 and new EM during follow-up 1) and 15 patients were not included due to absence of study investigator. Hence, 200 patients were included in the analysis: 100 patients were prescribed doxycycline and 100 ceftriaxone (Figure 1 ). Patients from both treatment groups were balanced for basic demographic and clinical characteristics at presentation (Table 1) .
Adverse events
All except seven patients were re-examined at 14 days and all stated compliance with taking the study drug. The changes in Treating multiple erythema migrans JAC laboratory values were minor and the proportions of patients with deviation from normal values were similar at baseline and 14 days after starting treatment; this was also the case when comparing the two treatment groups. There were no major complications regarding intravenous access in any of the ceftriaxone-treated patients. Patients who were treated with ceftriaxone experienced allergic reactions more frequently than patients who were prescribed doxycycline, yet the difference did not reach statistical significance (P " 0.01). Moreover, the frequency of any other drugrelated adverse event did not differ significantly between the two treatment groups (Table 2) .
Treatment outcome according to antibiotic regimen
The median duration of skin lesions after starting antibiotic treatment was the same in the doxycycline (7 days, IQR 7-12 days) and ceftriaxone (7 days, IQR 7-10 days) treatment groups (P " 0.15).
The proportion of patients with incomplete response, represented predominantly by the presence of post-Lyme symptoms, steadily decreased over the study period (Table 3 ). The large majority of patients in both treatment groups showed complete response from 2 months onward, returning to their pre-Lyme health status. At 12 months, 10/170 (5.9%) patients showed incomplete response. None of these patients with incomplete response at 12 months qualified as having 'post-Lyme disease syndrome', because the reported symptoms were not severe enough to result in any reduction of previous activity levels. 5 Failure was documented in one patient from each treatment Stupica et al.
group, because a residual skin lesion could still be seen at the 2 month visit. Both were retreated with oral antibiotics and had an uneventful further course. The logistic regression model for repeated measurements of incomplete response, with treatment regimen as the explanatory variable, adjusted for time from enrolment, sex, age and presence of constitutional symptoms at enrolment, indicated that the probability of incomplete response decreased with time from enrolment, most markedly between the 14 day and 2 month timepoints and between the 6 and 12 month timepoints. Patients treated with doxycycline had lower odds for incomplete response than those treated with ceftriaxone, but the difference was not significant (OR " 0.52, 95% CI 0.26-1.04; Table 4 ).
Only 5/152 (3.3%) patients who had a lumbar puncture demonstrated CSF pleocytosis (Table 1) ; only 1/5 patients reported headache at baseline, the others having no symptoms suggesting neurological involvement. All five had complete response at the 12 month follow-up. Intrathecal synthesis of borrelial IgM and/or IgG antibodies was identified in 14/152 patients (9.2%); none had had prior Lyme neuroborreliosis, none had signs/symptoms of neurological involvement at enrolment and only 3/14 had CSF pleocytosis.
Microbiological results
Seropositivity for borreliae at enrolment and during follow-up was similar for patients from both treatment groups. Borrelia burgdorferi sensu lato was isolated from pretreatment skin biopsy specimens in 88/161 (54.7%) patients who consented to the procedure. Among the isolates, 92.0% were Borrelia afzelii. Proportions of individual Borrelia species in the two treatment groups were similar. A re-biopsy was performed in 74/88 (84.1%) initially culture positive patients. All the re-biopsies were culture negative.
Comparison of non-specific symptoms in patients and controls
The control subjects did not differ significantly from the patients with regard to basic demographic parameters. There were no significant differences in the frequency or intensity of non-specific symptoms at enrolment and at 6 and 12 months post-enrolment between patients and controls. More detailed information is provided in Table 5 .
Discussion
The majority of studies on treatment of EM have focused exclusively or predominantly on patients with solitary EM. [12] [13] [14] [15] [16] [17] [18] [19] [20] In the only study of early disseminated Lyme borreliosis that specifically addressed patients with multiple EM (133/140 evaluated patients had multiple EM), oral doxycycline for 21 days and intravenous ceftriaxone for 14 days were equally effective in preventing subsequent manifestations of Lyme borreliosis. 6 The present study, which included solely patients with multiple EM, has shown that 14 day treatment with 100 mg of oral doxycycline twice daily was Upper bound of one-sided 95% CI for the absolute difference in proportion of patients with incomplete response between doxycycline and ceftriaxone groups; non-inferiority of doxycycline was accepted if it was 10 percentage points.
Treating multiple erythema migrans JAC not inferior to 2 g of intravenous ceftriaxone once daily and that both treatment regimens were highly effective in adult patients with multiple EM. The frequency of drug-related adverse events did not differ significantly between the two treatment groups; however, serious adverse events, namely anaphylaxis, were documented only among ceftriaxone-treated patients. The large majority of multiple EM patients in both treatment groups showed complete response from 2 months onward. Only two patients were classified as having treatment failure and were retreated with doxycycline or cefuroxime axetil, respectively, because of faint residua of EM skin lesion persisting at the 2 month visit. No histopathology examination was performed to assess whether the persistent lesion was associated with inflammation. Both patients were seropositive and skin culture negative at enrolment. They both remained seropositive during follow-up. One reported postLyme symptoms and the other was asymptomatic at the 6 and 12 month visits. It is questionable whether these cases truly represented a treatment failure because pale residua at the location of previous EM skin lesion may have represented post-inflammatory hyperpigmentation.
After starting antibiotic treatment, the duration of EM skin lesions was comparable (median 7 days) in patients treated with doxycycline or ceftriaxone. In both groups, the microbiological effectiveness was excellent (all skin re-biopsy specimens were culture negative for borreliae) and the incidence of incomplete response 1 year after antibiotic treatment was comparably low (4.9% in the doxycycline group and 6.8% in the ceftriaxone group).
Fewer than half of our multiple EM patients reported constitutional symptoms at enrolment. This is in contrast to findings in the USA, where the proportion of EM patients with constitutional symptoms is higher and haematogenous dissemination, clinically manifested as multiple EM, more frequent than in Europe. These differences have been attributed to distinct aetiology of Lyme borreliosis, which is caused nearly exclusively by B. burgdorferi sensu stricto in North America and predominantly by B. afzelii and Borrelia garinii in Europe, 4, [16] [17] [18] and to differences in the inflammatory responses elicited by American and European Borrelia species. 21, 22 In the present study, the high proportion of postLyme symptoms at the 14 day visit could also be due to interference from post-lumbar puncture symptoms in some patients.
The IDSA guidelines recommend the same management for multiple EM as for solitary EM. 5 However, some data suggest that the presence of multiple EM might predispose to less favourable treatment outcome. 13, 14, 20 Furthermore, in children with multiple EM, mild pleocytosis has been identified in 18%-26%, although none had frank clinical evidence of CNS involvement. 23 These findings might suggest that a safe treatment approach for multiple EM should be the same as for early Lyme neuroborreliosis, for which intravenous ceftriaxone or oral doxycycline is effective. 5, 24 In the present study, CSF pleocytosis, suggesting potential dissemination of borreliae to the CNS, was found only exceptionally (3.3%). In Data are presented as median (IQR), n (%) or n/n (%). a P value from v 2 test for categorical variables and from Mann-Whitney test for numerical variables. Because of multiple comparisons, a P value ,0.01 was considered significant. Statistical testing of categorical variables used Fisher's exact test, resulting in some P values estimated to be equal to 1.0. b Severity score of non-specific symptoms, based on a 10 cm visual analogue scale, with a score of 10 being the most severe.
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addition, reports on the favourable treatment outcome of oral doxycycline in early Lyme neuroborreliosis [25] [26] [27] imply that the question of potential CNS involvement in multiple EM patients is more of academic than practical significance.
In our logistic regression model, the probability of incomplete response decreased with time from enrolment and patients treated with doxycycline had lower odds for incomplete response than those treated with ceftriaxone, although the difference was not significant. The upper bound limit of the one-sided 95% CI for the absolute difference in the proportion of patients with incomplete response between the two treatment options to establish the non-inferiority of doxycycline was preselected at 10 percentage points. This difference seemed acceptable because in our previous studies we found that the post-Lyme symptoms were relatively mild and not incapacitating.
Control subjects reported the eight non-specific symptoms comparably often as patients. These findings clearly show that such symptoms, which are not synonymous for post-Lyme symptoms, should not automatically be attributed to previous Lyme borreliosis.
There are several limitations to our study. First, the study was not blinded, which may have resulted in more or fewer symptoms being reported in doxycycline-treated patients compared with ceftriaxone-treated patients. Second, some of the post-Lyme symptoms in the patients could have been misdiagnosed as being due to Lyme borreliosis. Third, the similar proportion of nonspecific symptoms in the patients and the control group does not rule out that some of these symptoms in patients were triggered by infection with borreliae. Fourth, we did not actively search for borrelial infection in the control group and some of their nonspecific symptoms might have been due to Lyme borreliosis. Fifth, the finding of non-inferiority of doxycycline versus ceftriaxone for treatment of multiple EM may not be extrapolated automatically to other oral antibiotics used for treatment of EM. Sixth, our results are expected to be applicable to European regions with similar ratios of B. afzelii causing EM, but may not entirely pertain to North America, where Lyme borreliosis is caused by B. burgdorferi sensu stricto. 2 In conclusion, to our knowledge this clinical study presents the largest reported series of patients with early Lyme borreliosis manifested as multiple EM. Our results show that 14 day oral doxycycline, with its several management advantages, was not inferior to intravenous ceftriaxone for treatment of multiple EM in adult patients in Europe. The frequency of non-specific constitutional symptoms in patients did not exceed the frequency of these symptoms in controls without a history of Lyme borreliosis; therefore, these symptoms should not be uncritically ascribed to borrelial infection.
